We’re looking for opportunities where we can add value, including products we can sell through our existing sales channels, or where we can drive further growth by investing in development and commercial activities.

BTG welcomes new opportunities for licensing and acquisition.

Our Business Development strategy is focused on opportunities that complement our current product portfolio, capabilities and overall growth strategy with a focus on late-stage development and marketed products.

Within Specialty Pharmaceuticals this includes Acute Care hospital products while our Interventional Medicine portfolio is centered on Interventional Oncology, Interventional Vascular and Interventional Pulmonology products and devices.

We are open to global or regional partnerships for products that can be sold through our dedicated Specialty Pharmaceuticals hospital-focused sales force and our Interventional Medicine commercial channels.

For Business Development opportunities, please send your enquiries to:
Charles Brigden
SVP, Head of Business Development
Gwen Melincoff
Vice President, Business Development
Russ Redshaw
Director, Business Development


  • 2COL_MODULE_THUMB (3).png

    About Us

    Healthcare is constantly evolving, so BTG never stands still. Inspired by a deep understanding of our customers’ needs, we endeavour to meaningfully improve health outcomes and the patient experience.

    Read more
  • 15 Oct 2015

    BTG’s Head of Business Development discusses M&A in UK biotech report

    Charles Brigden talks about BTG’s M&A track record in Building the Third Global Cluster: State of the Nation 2015—a report led by BioIndustry Association (BIA) and EY.

    Read the report here